Cerebrospinal fluid biomarkers in clinically isolated syndromes and multiple sclerosis

Proteomics - Clinical Applications

Volumn 1, Issue 9, 2007, Pages 963-971

  Fiorini, Michele ^a   Zanusso, Gianluigi ^a   Benedetti, Maria Donata ^a   Righetti, Pier Giorgio ^b   Monaco, Salvatore ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b POLITECNICO DI MILANO   (Italy)

Author keywords

Biomarker panels; Cerebrospinal fluid; Cystatin C; Multiple sclerosis; Tau protein

Indexed keywords

CYSTATIN C; ISOPROTEIN; NEUROLEPTIC AGENT; PROTEIN 14 3 3; TAU PROTEIN;

CEREBROSPINAL FLUID EXAMINATION; CREUTZFELDT JAKOB DISEASE; DEMENTIA; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE MARKER; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOBLOTTING; LUMBAR PUNCTURE; MOTOR NEURON DISEASE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN VARIANT; REVIEW; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

EID: 34447338986     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200700091     Document Type: Review

References (51)

1. Frohman, E. M., Racke, M. K., Raine, C. S., Multiple sclerosis. The plaque and its pathogenesis. N. Engl. J. Med. 2006, 354, 942-955.
2. Hauser, L. H., Oksenberg, J. R., The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006, 52, 61-76.
3. Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Bruck, W. et al., Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128, 2705-2712.
4. Confavreux, C., Vukusic, S., Moreau, T., Adeleine, P., Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 2000, 343, 1430-1438.
5. Korteweg, T., Tintore, M., Uitdehaag, B., Rovira, A. et al., MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study, Lancet Neurol. 2006, 5, 221-227.
6. Reindl, M., Khalil, M., Berger, T., Antibodies as biological markers for pathophysiological processes in MS. J. Neuroimmunol. 2006, 780, 50-62.
7. Berger, T., Rubner, P., Schautzer, F., Egg, R. et al., Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. Med. 2003, 349, 139-145.
8. Kuhle, J., Pohl, C., Mehling, M., Edan, G. et al., Lack of association between antimyelin antibodies and progression to multiple sclerosis. N. Engl. J. Med. 2007, 356, 371-378.
9. Lassmann, H., Axonal injury in multiple sclerosis. iJ. Neurol. Neurosurg. Psychiatry 2003, 74, 695-697.
10. Teunissen, C., Dijkstra, C., Polman, C., Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol. 2005, 4, 32-41.
11. Petzold, A., Eikelenboom, M. I., Keir, G., Polman, C. H. et al., The new global multiple sclerosis severity score (MSSS) correlates with axonal but not glial biomarkers. Mult. Scler. 2006, 12, 325-328.
12. Malmestrom, C., Haghighi, S., Rosengren, L., Andersen, O. et al., Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003, 61, 61720-61725.
13. Martinez-Yelamos, A., Saiz, A., Sanchez-Valle, R., Casado, V. et al., 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. Neurology 2001, 57, 722-724.
14. Bartosik-Psujek, H., Archelos, J. J., Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J. Neurol. 2004, 251, 414-420.
15. de Seze, J., Peoc'h, K., Ferriby, D., Stojkovic, T. et al., 14-3-3 Protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis. Neurology 2002, 249, 626-627.
16. Robinson, W. H., Utz, P. J., Steinman, L., Genomic and proteomic analysis of multiple sclerosis. Opinion. Curr. Opin. Immunol. 2003, 15, 660-667.
17. Dumont, D., Noben, J. P., Raus, J., Stinissen, P., Robben, J., Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 2004, 4, 2117-2124.
18. Noben, J. P., Dumont, D., Kwasnikowska, N., Verhaert, P. et al., Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J. Proteome Res. 2006, 5, 1647-1657.
19. Hamdan, M, Righetti, P. G., Proteomics Today- Protein Assessment and Biomarkers Using Mass Spectrometry, 2-D Electrophoresis and Microarray Technology, Wiley-VCH, Hoboken, 2005.
20. Bielekova, B., Martin, R., Development of biomarkers in multiple sclerosis. Brain 2004, 127, 1463-1478.
21. McDonald, W. I., Compston, A., Edan, G. et al., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50, 121-127.
22. Kurtzke, J. F., Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33, 1444-1452.
23. Boston, P. F., Jackson, P., Kynoch, P. A. M., Human 14-3-3 protein: radioimmunoassay, tissue distribution, and cerebrospinal fluid levels in patients with neurological disorders. J. Neurochem. 1982, 38, 1466-1474.
24. Berg, D., Holzmann, C., Riess, O., 14-3-3 proteins in the nervous system. Nature Rev. Neurosci. 2003, 4, 752-762.
25. Hsich, G., Kenney, K., Gibbs, C. J., Lee, K. H., Harrington, M. G., The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. New Engl. J. Med. 1996, 13, 924-930.
26. Piubelli, C., Fiorini, M., Zanusso, G., Milli, A., Fasoli, E., Monaco, S., Righetti, P, G., Searching for markers of Creutzfeldt-Jakob disease in cerebrospinal fluid by two-dimensional mapping. Proteomics 2006, 6, S256-S261.
27. Martinez-Yelamos, A., Rovira, A., Sanchez-Valle, R., Martinez-Yelamos, S., Tintoré, M. et al., CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS. J. Neurol. 2004, 251, 1278-1279.
28. Bersano, A., Fiorini, M., Allaria, S., Zanusso, G. et al., Detection of CSF 14-3-3 protein in Guillain-Barre syndrome. Neurology 2006, 67, 2211-2216.
29. Satoh, J., Yamamura, T., Arima, K., The 14-3-3 protein epsilon isoform expressed in reactive astrocytes in demyelinating lesions of multiple sclerosis binds to vimentin and glial fibrillary acidic protein in cultured human astrocytes. Am. J. Pathol. 2004, 165, 577-592.
30. Shahani, N., Brandt, R., Functions and malfunctions of the tau proteins. Cell. Mol. Life Sci. 2002, 59, 1668-1680.
31. Goedert, M., Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci. 1993, 16, 460-465.
32. Hulstaert, F., Blennow, K., Ivanoiu, A., Schoondrewaldt, H. C. et al., Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999, 52, 1555-1562.
33. Andreasen, N., Minthon, L., Clarberg, A., Davodsson, P. et al., Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 1999, 53, 1488-1492.
34. Jimenez-Jimenez, F. J., Zurdo, J. M., Hernanz, A., Medina-Acebron, S. et al., Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol. Scand. 2002, 106, 351-354.
35. Monaco, S., Zanusso, G., Mazzucco, S., Rizzuto, N., Cerebral amyloidoses: molecular pathways and therapeutic challenges. Curr. Med. Chem. 2006, 13, 1903-1913.
36. Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L. et al., Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003, 289, 2094-2103.
37. Reed, C. H., Diagnostic applications of cystatin C. Sr. J. Biomed. Sci. 2000, 57, 323-329.
38. Kalman, J., Marki-Zay, J., Juhasz, A., Santha, A. et al., Serum and cerebrospinal fluid cystatin C levels in vascular and Alzheimer's dementia. Acta Neurol. Scand. 2000, 101, 279-282.
39. Nagai, A., Terashima, M., Harada, T., Shimode, K. et al., Cathepsin B and H activities and cystatin C concentrations in cerebrospinal fluid from patients with leptomeningeal metastasis. Clin. Chim. Acta. 2003, 329, 53-60.
40. Nagai, A., Murakawa, Y., Terashima, M., Shimode, K. et al., Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases. Neurology 2000, 55, 1828-1832.
41. Sanchez, J. C., Guillaume, E., Lescuyer, P., Allard, L. et al., Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2004, 4, 2229-2233.
42. Ma, J., Tanaka, K. F., Yamada, G., Ikenada, K., Induced expression of cathepsins and cystatin C in a murine model of demyelination. Neurochem. Res. 2007, 32, 311-320.
43. Hu, S., Loo, J. A., Wong, D. T., Human body fluid proteome analysis. Proteomics 2006, 6, 6326-6353.
44. Villanueva, J., Philip, J., Entenberg, D., Chaparro, C. A. et al., Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 2004, 76, 1560-1570.
45. Liotta, L. A., Petricoin, E. F., Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J. Clin. Invest. 2006, 716, 26-30.
46. Geho, D. H., Liotta, L. A., Petricoin, E. F., Zhao, W., Araujo, R. P., The amplified peptidome: the new treasure chest of candidate biomarkers. Curr. Opin. Chem. Biol. 2006, 10, 50-55.
47. Selle, H., Lamerz, J., Buerger, K., Dessauer, A., Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease. Comb. Chem. High. Throughput Screen. 2005, 8, 801-806.
48. Yuan, X., Desiderio, D. M., Human cerebrospinal fluid peptidomics. J. Mass Spectrom. 2005 40, 176-181.
49. Hammack, B. N., Fung, K. Y., Hunsucker, S. W., Duncan, M. et al., Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult. Scler. 2004, 10, 245-260.
50. Irani, D. N., Anderson, C., Gundry, R., Cotter, R. et al., Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann. Neurol. 2006, 59, 237-247.
51. Hansson, S. F., Hviid Simonsen, A., Zetterberg, H., Andersen, O. et al., Cystatin C in cerebrospinal fluid and multiple sclerosis. Ann. Neurol. 2006 [Epub ahead of print]